Renal Medullary Carcinoma: A Case Report and Brief Review of the Literature

REFERENCES

1. ↵
   1. Siegel R,
   2. Naishadham D,
   3. Jemal A

   (1, 2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30, pmid:23335087, Epub 2013 Jan 17.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Chowdhury S,
   2. Matrana MR,
   3. Tsang C,
   4. Atkinson B,
   5. Choueiri TK,
   6. Tannir NM

   (8, 2011) Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 25(4):853–869, pmid:21763971.

   OpenUrlCrossRefPubMed
3. ↵
   1. Davis CJ Jr.,
   2. Mostofi FK,
   3. Sesterhenn IA

   (1, 1995) Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19(1):1–11, pmid:7528470.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Berman LB

   (6 3, 1974) Sickle cell nephropathy. JAMA 228(10):1279, pmid:4406521.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Srigley JR,
   2. Delahunt B

   (6, 2009) Uncommon and recently described renal carcinomas. Mod Pathol 22(Suppl 2):S2–S23, pmid:19494850.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Sathyamoorthy K,
   2. Teo A,
   3. Atallah M

   (5, 2006) Renal medullary carcinoma in a patient with sickle-cell disease. Nat Clin Pract Urol 3(5):279–283, pmid:16691241, quiz 289.

   OpenUrlCrossRefPubMed
7. ↵
   1. Patel K,
   2. Livni N,
   3. Macdonald D

   (1, 2006) Renal medullary carcinoma, a rare cause of haematuria in sickle cell trait. Br J Haematol 132(1):1, pmid:16371012.

   OpenUrlCrossRefPubMed
8. ↵
   1. Yan BC,
   2. Mackinnon AC,
   3. Al-Ahmadie HA

   (7, 2009) Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. Arch Pathol Lab Med 133(7):1026–1032, pmid:19642729.

   OpenUrlPubMed
9. ↵
   1. Tannir NM,
   2. Lim ZD,
   3. Bekele BN,
   4. et al.

   (2011) Outcome of patients with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 29((Suppl 7)), abstract 386.
10. ↵
    1. Baig MA,
    2. Lin YS,
    3. Rasheed J,
    4. Mittman N

    (7, 2006) Renal medullary carcinoma. J Natl Med Assoc 98(7):1171–1174, pmid:16895289.

    OpenUrlPubMed
11. ↵
    1. Albadine R,
    2. Wang W,
    3. Brownlee NA,
    4. et al.

    (8, 2009) Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol 182(2):735–740, pmid:19539329, Epub 2009 Jun 18.

    OpenUrlCrossRefPubMed
12. ↵
    1. Schaeffer EM,
    2. Guzzo TJ,
    3. Furge KA,
    4. et al.

    (7, 2010) Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 106(1):62–65, pmid:20002663, Epub 2009 Dec 11.

    OpenUrlPubMed
13. ↵
    1. Cheng JX,
    2. Tretiakova M,
    3. Gong C,
    4. Mandal S,
    5. Krausz T,
    6. Taxy JB

    (6, 2008) Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 21(6):647–652, pmid:18327209, Epub 2008 Mar 7.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Mariño-Enríquez A,
    2. Ou WB,
    3. Weldon CB,
    4. Fletcher JA,
    5. Pérez-Atayde AR

    (3, 2011) ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 50(3):146–153, pmid:21213368, Epub 2010 Dec 13.

    OpenUrlCrossRefPubMed
15. ↵
    1. Matrana MR,
    2. Atkinson B,
    3. Jonasch E,
    4. Tannir NM

    (8, 2011) Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol 6(3):189–198, pmid:21827388.

    OpenUrlCrossRefPubMed
16. ↵
    1. Kondagunta GV,
    2. Drucker B,
    3. Schwartz L,
    4. et al.

    (9 15, 2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22(18):3720–3725, pmid:15365068.

    OpenUrlAbstract/FREE Full Text